← The library
Danuglipron
PF-06882961, discontinuedNot a peptide · small-molecule pillMetabolic/WeightEvidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
PurposeMetabolic / Weight loss
MechanismOral small-molecule GLP-1 receptor agonist.
EffectsDevelopment for chronic weight management was discontinued by Pfizer before any approval.
DosingNo human dose established.
Bottom lineIncluded so the record is complete. It was discontinued, and the reason was liver injury.
Batches on filenone
No tested batches on file.
Read with
The library records no pairings for this entry.
Cautions & interactions
Discontinued over a liver safety signal. Across a safety database of more than 1,400 participants, liver enzyme elevations were in line with approved agents in the class, but one asymptomatic participant experienced potential drug-induced liver injury, which resolved on stopping the drug.
Not applicable; the compound is not in use.
CV 1 of 5 — No cardiovascular outcomes data; development ended before that stage.